Neptune Technologies & Bioressources Inc (NTB.TO) 2.34 $NTB.TO
Neptune Announces First Quarter Results
GlobeNewswire - Wed Jul 16, 3:53AM CDT
Neptune Technologies & Bioressources Inc. ("Neptune" or the "Corporation"

(Nasdaq:NEPT) (TSX:NTB), announces its consolidated financial results for the first quarter ended May 31, 2014.
Neptune to Hold Conference Call to Discuss First Quarter Results
GlobeNewswire - Tue Jul 08, 8:23AM CDT
Neptune Technologies & Bioressources Inc. ("Neptune" or the "Corporation"

(Nasdaq:NEPT) (TSX:NTB), announced today that it will be holding a conference call on Thursday July 17 at 9:00 AM (ET) to present its results for the first quarter ended May 31, 2014.
Neptune Receives Composition Patent in Australia
GlobeNewswire - Mon Jun 23, 6:00AM CDT
Neptune Technologies & Bioressources Inc. ("Neptune" or the "Corporation"

(Nasdaq:NEPT) (TSX:NTB), announces that that the Australian Patent Office has granted Neptune a patent (the "Patent"

covering omega-3 phospholipids comprising polyunsaturated fatty acids, one of the main bioactive ingredients in all recognized krill oils. The patent is granted for the Australian market and is valid until 2022.
NeuroBioPharm Reports Results of Annual General Meeting
GlobeNewswire - Fri Jun 20, 8:58AM CDT
NeuroBioPharm Inc. ("NeuroBio" or the "Corporation"

a Neptune Technologies & Bioressources Inc. subsidiary ("Neptune"

(Nasdaq:NEPT) (TSX:NTB) announces that at its Annual General Meeting (the "Meeting"

, held on June 19, 2014, the Corporation's shareholders voted in favour of all items put forth at the Meeting and outlined in the Corporation's management proxy circular dated May 22, 2014 (the "Circular"

available on SEDAR at www.sedar.com and EDGAR at www.sec.gov/edgar.shtml.
Neptune Reports Results of Annual and Special Meeting
GlobeNewswire - Fri Jun 20, 8:58AM CDT
Neptune Technologies & Bioressources Inc. ("Neptune" or the "Corporation"

(Nasdaq:NEPT) (TSX:NTB), announces that at its Annual and Special Meeting (the "Meeting"

, held on June 19, 2014, the Corporation's shareholders voted in favour of all items put forth at the Meeting and outlined in the Corporation's management proxy circular dated May 22, 2014 (the "Circular"

available on SEDAR at www.sedar.com and EDGAR at www.sec.gov/edgar.shtml.
Neptune Sherbrooke Plant to Resume Production
GlobeNewswire - Fri Jun 13, 7:00AM CDT
Neptune Technologies & Bioressources Inc. ("Neptune" or the "Corporation"

(Nasdaq:NEPT) (TSX:NTB), announced today that its Sherbrooke, Quebec, Canada production facility has received all required operating permits and production will now resume.
Neptune, Acasti and NeuroBioPharm Announce Litigation Regarding its Former Chief Executive Officer
Marketwire - Fri May 30, 7:02AM CDT
Neptune Technologies & Bioressources Inc. ("Neptune"

(TSX: NTB)(NASDAQ: NEPT), Acasti Pharma Inc. ("Acasti"

(TSX VENTURE: APO)(NASDAQ: ACST) and NeuroBioPharm Inc. ("NeuroBio"

today jointly announce that Henri Harland, the former President and Chief Executive Officer of each of Neptune, Acasti and NeuroBio, has filed a lawsuit against Neptune and its subsidiaries in connection with his departure as President and Chief Executive Officer of each of Neptune, Acasti and NeuroBio. Mr. Harland resigned as President and Chief Executive Officer of Neptune, Acasti and NeuroBio on April 28, 2014.
Neptune, Acasti and NeuroBioPharm Announce Appointment of Interim CEO
GlobeNewswire - Fri May 23, 7:00AM CDT
Neptune Technologies & Bioressources Inc. ("Neptune"

(Nasdaq:NEPT) (TSX:NTB), Acasti Pharma Inc. ("Acasti"

(Nasdaq:ACST) (TSX-V:APO) and NeuroBioPharm Inc. ("NeuroBio"

(collectively the "Corporation"

today jointly announce the appointment of Andre Godin as interim President and Chief Executive Officer of Neptune, Acasti and NeuroBio with immediate effect.
Neptune Announces Fourth Quarter and Fiscal Year Results
GlobeNewswire - Wed May 21, 4:28PM CDT
Neptune Technologies & Bioressources Inc. ("Neptune" or the "Corporation"

(Nasdaq:NEPT) (TSX:NTB), announces its consolidated financial results for the fourth quarter and fiscal year ended February 28, 2014.
NeuroBioPharm Announces Resignation of Chief Financial Officer
GlobeNewswire - Tue May 20, 7:06AM CDT
NeuroBioPharm ("NeuroBio" or the "Corporation"

a Neptune Technologies & Bioressources Inc. subsidiary ("Neptune"

(Nasdaq:NEPT) (TSX:NTB) announces the resignation of Frederic Harland as Chief Financial Officer of NeuroBio with immediate effect.
Neptune & Acasti Give Update on Patent Litigations With Enzymotec
GlobeNewswire - Tue Apr 01, 1:25PM CDT
Neptune Technologies & Bioressources Inc. ("Neptune"

(Nasdaq:NEPT) (TSX:NTB) and Acasti Pharma Inc. ("Acasti"

(Nasdaq:ACST) (TSX-V:APO), a Neptune subsidiary, announce that they have been unable to conclude a final settlement agreement through mediation with Enzymotec Ltd. and Enzymotec USA, Inc. (collectively, "Enzymotec"

that would resolve the International Trade Commission ("ITC"

investigation into infringement of Neptune's composition of matter patents, as well as related federal court actions initiated by Neptune against Enzymotec and its distributors. Neptune and Acasti will now pursue Enzymotec through the ITC and the federal district court in Delaware.
Neptune Provides Update on Sherbrooke Plant
GlobeNewswire - Thu Mar 27, 6:45AM CDT
Neptune Technologies & Bioressources Inc. ("Neptune" or the "Corporation"

(Nasdaq:NEPT) (TSX:NTB), announced today that reconstruction of its Sherbrooke, Quebec, Canada production facility will be completed April 7, 2014. Neptune is currently conducting equipment and safety related tests at the plant and employees are being trained. Preoperational testing will start early April 2014, with actual production commencing upon receipt of all outstanding permits.
NeuroBioPharm Extends Life of Warrants and Provides Other Corporate Updates
GlobeNewswire - Tue Mar 18, 1:14PM CDT
NeuroBioPharm Inc. ("NeuroBio" or the "Corporation"

, a Neptune Technologies & Bioressources Inc. subsidiary ("Neptune"

(Nasdaq:NEPT) (TSX:NTB), announces that it has extended the life of its Series 2011-1 common share purchase warrants, initiated a royalty prepayment process with Neptune and appointed a new CFO.
Neptune Announces Closing of the Over-Allotment Option Associated with its Recently Completed Public Offering of Common Shares
PR Newswire - Thu Mar 06, 10:53AM CST
Neptune Technologies & Bioressources Inc. ("Neptune"

(NASDAQ.NEPT - TSX.NTB), announced today that the syndicate of underwriters led by of Euro Pacific Canada Inc. and Roth Capital Partners, as Joint Book-Running Managers, and National Securities Corporation, a wholly owned subsidiary of National Holdings, Inc. (NHLD) as Lead Manager, have exercised in full the over-allotment option to purchase an additional 1,500,000 common shares of Neptune at a price of US$2.50 per common share in connection with Neptune's previously announced public offering, completed on March 5, 2014. As a result of the exercise of the over-allotment option, Neptune received additional gross proceeds of US$3.75 million for total gross proceeds of US$28.75 million.
Neptune Announces Closing of US$25.0 Million Underwritten Offering of Common Shares
CNW Group - Wed Mar 05, 8:11AM CST
Neptune Technologies & Bioressources Inc. ("Neptune"

(NASDAQ.NEPT - TSX.NTB), a biotechnology company engaged primarily in the development, manufacture and commercialization of marine-derived omega-3 polyunsaturated fatty acids, announced today the closing of its previously announced public offering of 10,000,000 common shares at US$2.50 per common share for gross proceeds of US$25.0 million. Euro Pacific Canada Inc. and Roth Capital Partners, LLC acted as Joint Book-Running Managers for the offering and National Securities Corporation, a wholly owned subsidiary of National Holdings, Inc. (NHLD), acted as Lead Manager.
Neptune Announces Pricing of US$25 Million Offering of Common Shares
GlobeNewswire - Fri Feb 28, 7:34AM CST
Neptune Technologies & Bioressources Inc. ("Neptune" or the "Company"

(Nasdaq:NEPT) (TSX:NTB), a biotechnology company engaged primarily in the development, manufacture and commercialization of marine-derived omega-3 polyunsaturated fatty acids, announced today that it has priced an underwritten public offering of 10,000,000 newly issued common shares at a public offering price of US$2.50 per share.
Neptune Announces Proposed Offering of Common Shares
CNW Group - Thu Feb 27, 3:59PM CST
Neptune Technologies & Bioressources Inc. ("Neptune" or the "Company"

(NASDAQ.NEPT) (TSX.NTB), a biotechnology company engaged primarily in the development, manufacture and commercialization of marine-derived omega-3 polyunsaturated fatty acids, announced today that it has commenced an underwritten public offering of its common shares. The offering is being conducted in the United States pursuant to the Company's effective shelf registration statement filed with the U.S. Securities and Exchange Commission ("SEC"

and in Canada pursuant to a final short form base shelf prospectus filed with the securities regulatory authorities in the Provinces of Québec, Ontario, Manitoba, Alberta and British Columbia. The number of common shares to be issued and the price of each common share will be determined at the time of pricing of the offering.